This trial assessed adding an infusion of the drug nivolumab—or a placebo—to the pre-surgery phase and then assessing how patients respond overall, and the practice changing results have been ...

For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

The immunotherapy used in the trial was nivolumab ( Opdivo ), a drug delivered intravenously that works by disabling a ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Three trials presented at ASCO GI 2025 will change practice and improve the treatment of colorectal cancer, according to experts.

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that could position them as new standards of care in certain subtypes of ...

The trial demonstrated that bi-immunotherapy with ipilimumab and nivolumab administered before surgery, followed by tailored adjuvant therapy based on pathologic response, significantly ...

This trial is designed for patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022 ...

Adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.